vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and PROTHENA CORP PUBLIC LTD CO (PRTA). Click either name above to swap in a different company.
Prime Medicine, Inc. is the larger business by last-quarter revenue ($838.0K vs $21.0K, roughly 39.9× PROTHENA CORP PUBLIC LTD CO). On growth, Prime Medicine, Inc. posted the faster year-over-year revenue change (-61.6% vs -99.0%).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
PRME vs PRTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $21.0K |
| Net Profit | $-46.1M | — |
| Gross Margin | — | — |
| Operating Margin | -5800.5% | — |
| Net Margin | -5498.7% | — |
| Revenue YoY | -61.6% | -99.0% |
| Net Profit YoY | -9.0% | 62.7% |
| EPS (diluted) | $-0.22 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | $21.0K | ||
| Q3 25 | $1.2M | $2.4M | ||
| Q2 25 | $1.1M | $4.4M | ||
| Q1 25 | $1.5M | $2.8M | ||
| Q4 24 | $2.2M | $2.1M | ||
| Q3 24 | — | $970.0K | ||
| Q2 24 | $0 | $132.0M | ||
| Q1 24 | $591.0K | $50.0K |
| Q4 25 | $-46.1M | — | ||
| Q3 25 | $-50.6M | $-36.5M | ||
| Q2 25 | $-52.6M | $-125.8M | ||
| Q1 25 | $-51.9M | $-60.2M | ||
| Q4 24 | $-42.3M | — | ||
| Q3 24 | — | $-59.0M | ||
| Q2 24 | $-55.3M | $66.9M | ||
| Q1 24 | $-45.8M | $-72.2M |
| Q4 25 | -5800.5% | — | ||
| Q3 25 | -4406.0% | -1666.3% | ||
| Q2 25 | -4787.2% | -1914.4% | ||
| Q1 25 | -3603.3% | -2319.0% | ||
| Q4 24 | -2025.7% | — | ||
| Q3 24 | — | -6857.0% | ||
| Q2 24 | — | 44.2% | ||
| Q1 24 | -8179.5% | -163056.0% |
| Q4 25 | -5498.7% | — | ||
| Q3 25 | -4129.1% | -1513.1% | ||
| Q2 25 | -4716.7% | -2845.4% | ||
| Q1 25 | -3568.8% | -2128.5% | ||
| Q4 24 | -1936.6% | — | ||
| Q3 24 | — | -6082.6% | ||
| Q2 24 | — | 50.7% | ||
| Q1 24 | -7743.0% | -144478.0% |
| Q4 25 | $-0.22 | — | ||
| Q3 25 | $-0.32 | $-0.68 | ||
| Q2 25 | $-0.41 | $-2.34 | ||
| Q1 25 | $-0.40 | $-1.12 | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | — | $-1.10 | ||
| Q2 24 | $-0.46 | $1.22 | ||
| Q1 24 | $-0.44 | $-1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $307.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $280.5M |
| Total Assets | $342.7M | $326.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | $307.5M | ||
| Q3 25 | $71.4M | $330.8M | ||
| Q2 25 | $53.8M | $371.4M | ||
| Q1 25 | $91.9M | $417.9M | ||
| Q4 24 | $182.5M | $471.4M | ||
| Q3 24 | — | $519.3M | ||
| Q2 24 | $55.6M | $564.1M | ||
| Q1 24 | $94.2M | $546.5M |
| Q4 25 | $120.9M | $280.5M | ||
| Q3 25 | $161.8M | $295.0M | ||
| Q2 25 | $60.9M | $324.3M | ||
| Q1 25 | $106.9M | $437.7M | ||
| Q4 24 | $153.1M | $486.9M | ||
| Q3 24 | — | $534.4M | ||
| Q2 24 | $196.6M | $581.9M | ||
| Q1 24 | $243.8M | $502.4M |
| Q4 25 | $342.7M | $326.8M | ||
| Q3 25 | $385.0M | $352.6M | ||
| Q2 25 | $279.0M | $399.1M | ||
| Q1 25 | $328.2M | $495.3M | ||
| Q4 24 | $297.5M | $547.1M | ||
| Q3 24 | — | $595.3M | ||
| Q2 24 | $259.7M | $645.6M | ||
| Q1 24 | $311.4M | $623.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-163.6M |
| Free Cash FlowOCF − Capex | $-37.5M | — |
| FCF MarginFCF / Revenue | -4480.4% | — |
| Capex IntensityCapex / Revenue | 34.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | $-163.6M | ||
| Q3 25 | $-35.0M | $-40.6M | ||
| Q2 25 | $-41.4M | $-46.3M | ||
| Q1 25 | $-48.9M | $-53.4M | ||
| Q4 24 | $16.2M | $-150.1M | ||
| Q3 24 | — | $-45.2M | ||
| Q2 24 | $-45.5M | $16.0M | ||
| Q1 24 | $-67.7M | $-73.1M |
| Q4 25 | $-37.5M | — | ||
| Q3 25 | $-35.3M | — | ||
| Q2 25 | $-43.0M | — | ||
| Q1 25 | $-51.3M | — | ||
| Q4 24 | $14.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-47.4M | — | ||
| Q1 24 | $-70.0M | — |
| Q4 25 | -4480.4% | — | ||
| Q3 25 | -2880.5% | — | ||
| Q2 25 | -3855.1% | — | ||
| Q1 25 | -3526.8% | — | ||
| Q4 24 | 662.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -11849.6% | — |
| Q4 25 | 34.6% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 141.0% | — | ||
| Q1 25 | 166.6% | — | ||
| Q4 24 | 82.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 393.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
